Krystal Biotech, Inc.
KRYS
Rankning i aktier
#2124
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Aktiekurs
$326.41
Marknadsvärde
$9.66B
Förändring (1 dag)
1.92%
Förändring (1 år)
66.57%
Land
US
Handel Krystal Biotech, Inc. (KRYS)
Kategori
Healthcare
Vinst för Krystal Biotech, Inc. (KRYS)
Vinst i Jun 2026 TTM: $226.62M
Enligt de senaste finansiella rapporterna från Krystal Biotech, Inc. är företagets nuvarande vinst $226.62M. År 2023 hade företaget en vinst på $12.90M, en ökning jämfört med vinsten år 2022 som var $-139.98M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Krystal Biotech, Inc. från 2016 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $226.62M | 137.66% |
| 2024 | $95.36M | 639.37% |
| 2023 | $12.90M | -109.21% |
| 2022 | $-139.98M | 101.20% |
| 2021 | $-69.57M | 116.28% |
| 2020 | $-32.17M | 68.52% |
| 2019 | $-19.09M | 75.30% |
| 2018 | $-10.89M | 37.49% |
| 2017 | $-7.92M | 588.70% |
| 2016 | $-1.15M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | 2,227.64% |
US
|
|
| $-3.09B | -1,462.19% |
US
|
|
| $-4.02B | -1,872.22% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 760.76% |
NL
|
